Search research articles
Contact Us
Filters
Showing results (81-90 of 139) with videos related to
Page
of 14
Sort By:
Zeitschrift Fur Gastroenterologie
|
September 1, 1995
Measurement of transit disorders in different gastrointestinal segments of patients with diabetes mellitus in relation to duration and severity of the disease by use of the metal-detector test
C Folwaczny, K Hundegger, C Volger, et al.
Der Radiologe
|
October 19, 2007
[Developments and perspectives in radioablative techniques]
T F Jakobs, R-T Hoffmann, K Tatsch, et al.
European Journal of Nuclear Medicine
|
July 7, 2001
18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study
R Tiling, R Linke, M Untch, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1994
Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI
G Arnold, K Tatsch, W H Oertel, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
August 14, 1998
Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography
G D Borasio, R Linke, J Schwarz, et al.
Journal of Neuro-Oncology
|
June 5, 2003
Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times
C Goetz, P Riva, G Poepperl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 1, 1997
Comparison of technetium-99m-sestamibi scintimammography with contrast-enhanced MRI for diagnosis of breast lesions
R Tiling, H Sommer, M Pechmann, et al.
Neurology
|
March 1, 1992
123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism
J Schwarz, K Tatsch, G Arnold, et al.
Neurology
|
December 1, 1993
123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism
J Schwarz, K Tatsch, G Arnold, et al.
Nuklearmedizin. Nuclear Medicine
|
July 12, 2002
[Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)]
G Pöpperl, C Götz, F J Gildehaus, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 139) with videos related to
Sort By:
Page
of 14
Zeitschrift Fur Gastroenterologie
|
September 1, 1995
Measurement of transit disorders in different gastrointestinal segments of patients with diabetes mellitus in relation to duration and severity of the disease by use of the metal-detector test
C Folwaczny, K Hundegger, C Volger, et al.
Der Radiologe
|
October 19, 2007
[Developments and perspectives in radioablative techniques]
T F Jakobs, R-T Hoffmann, K Tatsch, et al.
European Journal of Nuclear Medicine
|
July 7, 2001
18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study
R Tiling, R Linke, M Untch, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1994
Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI
G Arnold, K Tatsch, W H Oertel, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
August 14, 1998
Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I-123] IPT single photon emission computed tomography
G D Borasio, R Linke, J Schwarz, et al.
Journal of Neuro-Oncology
|
June 5, 2003
Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times
C Goetz, P Riva, G Poepperl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 1, 1997
Comparison of technetium-99m-sestamibi scintimammography with contrast-enhanced MRI for diagnosis of breast lesions
R Tiling, H Sommer, M Pechmann, et al.
Neurology
|
March 1, 1992
123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism
J Schwarz, K Tatsch, G Arnold, et al.
Neurology
|
December 1, 1993
123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism
J Schwarz, K Tatsch, G Arnold, et al.
Nuklearmedizin. Nuclear Medicine
|
July 12, 2002
[Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)]
G Pöpperl, C Götz, F J Gildehaus, et al.
Page
of 14